Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Elucidating The Pan-oncologic Landscape Of S100a9: Prognostic And Therapeutic Corollaries From An Integrative Bioinformatics And Mendelian Randomization Analysis.

Elucidating the pan-oncologic landscape of S100A9: prognostic and therapeutic corollaries from an integrative bioinformatics and Mendelian randomization analysis.

Yingying Chen1, Zixuan Wu2, Xingxing Yi3

  • 1The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.

Scientific Reports
|August 17, 2024

Related Experiment Videos

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

370
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

View abstract on PubMed

Summary
This summary is machine-generated.

The calcium-binding protein S100A9 is a significant factor in cancer, impacting prognosis and immune response. This study reveals its potential as a prognostic biomarker and therapeutic target across various cancers.

Area of Science:

  • Oncology
  • Bioinformatics
  • Genomics

Background:

  • S100A9 is a calcium-binding protein implicated in various cancers.
  • Its role in cancer progression and patient outcomes requires comprehensive investigation.

Purpose of the Study:

  • To investigate the prognostic and therapeutic potential of S100A9 across diverse cancer types using bioinformatics.
  • To analyze S100A9's relationship with tumor mutational burden, microsatellite instability, and immune cell infiltration.

Main Methods:

  • Utilized bioinformatics tools and public cancer genomics databases (e.g., TCGA).
  • Conducted differential expression analysis, mutational burden assessment, protein interaction network analysis, and survival analysis.
  • Examined S100A9's association with TMB, MSI, DNA methylation, and immune cell infiltration.
Keywords:
Cancer heterogeneityImmune infiltrationMicrosatellite instabilityPrognosis

Related Experiment Videos

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions
09:00

A Streamlined Approach for Mass Spectrometry-Based Proteomics Using Selected Tissue Regions

Published on: April 18, 2025

370
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.0K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

Main Results:

  • S100A9 exhibits heterogeneous expression across human cancers, with elevated levels in BLCA, CESC, COAD, ESCA, and GBM.
  • S100A9 expression correlates with prognosis variably across cancer types and is associated with TMB and MSI in nine cancer types.
  • S100A9 influences the tumor immune microenvironment, showing negative correlation with most immune cells but positive correlation with neutrophils, M1 macrophages, and activated NK cells.

Conclusions:

  • S100A9 is a significant player in cancer progression, offering valuable prognostic insights.
  • S100A9 serves as a potential prognostic biomarker and therapeutic target for cancer management.
  • Modulating S100A9 activity may significantly impact cancer treatment strategies.
S100A9
Tumor mutational burden